MCM
PTCT icon

Moore Capital Management’s PTC Therapeutics PTCT Stock Holding History

Moore Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-30,500
Closed -$684K – 521
2023
Q3 		$684K Buy
+30,500
New +$1.13M 0.01% 322
2015
Q3 		– Sell
-50,000
Closed -$2.41M – 378
2015
Q2 		$2.41M Buy
+50,000
New +$2.92M 0.05% 294

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Moore Capital Management's PTCT Position: Q1 2026 in Review

Moore Capital Management opened a new position in PTC Therapeutics (PTCT) in Q1 2026: 44,694 shares worth $3.05M. The stake represents 0.06% of the portfolio and ranks #223 among its holdings. This is a return to the name: Moore Capital Management previously reported a position in PTCT as recently as Q2 2023.

Moore Capital Management first reported a position in PTCT in Q1 2015 and has held it in 31 quarters since. The position peaked at $10.1M in Q4 2019. 350 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Moore Capital Management held 44,694 shares of PTC Therapeutics worth $3.05M as of Q1 2026.
  • PTC Therapeutics was a new Moore Capital Management position in Q1 2026.
  • PTC Therapeutics made up 0.06% of Moore Capital Management's portfolio in Q1 2026, its #223 holding.
  • Moore Capital Management first reported a position in PTC Therapeutics in Q1 2015 and has held it in 31 quarters since.
  • Moore Capital Management's PTC Therapeutics position peaked at $10.1M in Q4 2019.
  • 350 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.